What is the current valuation of the UK ophthalmic drugs market?

As of 2024, the UK ophthalmic drugs market was valued at 2.06 USD Billion. Read More

What is the projected market size for the UK ophthalmic drugs market by 2035?

The market is projected to reach 3.8 USD Billion by 2035. Read More

What is the expected CAGR for the UK ophthalmic drugs market during the forecast period?

The expected CAGR for the UK ophthalmic drugs market from 2025 to 2035 is 5.73%. Read More

Which therapeutic areas are driving growth in the UK ophthalmic drugs market?

Key therapeutic areas include Glaucoma, Infection, Dry Eye Syndrome, Allergic Conjunctivitis, and Retinal Disorders. Read More

What are the leading companies in the UK ophthalmic drugs market?

Key players include Novartis, Roche, Allergan, Bausch Health, Santen Pharmaceutical, Hoya Corporation, Merck & Co., Pfizer, and Johnson & Johnson. Read More

How does the market segment by application in the UK ophthalmic drugs market?

The market segments by application include Anti-Inflammatory, Antibiotic, Antiglaucoma, Lubricants, and Antiviral. Read More

What are the projected values for eye drops in the UK ophthalmic drugs market?

The projected value for eye drops is expected to increase from 0.82 USD Billion in 2024 to 1.5 USD Billion by 2035. Read More

What formulations are available in the UK ophthalmic drugs market?

Formulations include Eye Drops, Ointments, Gels, Injectables, and Implants. Read More

What routes of administration are utilized in the UK ophthalmic drugs market?

The market utilizes Topical, Systemic, Intravitreal, Subconjunctival, and Periocular routes of administration. Read More

What is the growth outlook for the anti-inflammatory segment in the UK ophthalmic drugs market?

The anti-inflammatory segment is projected to grow from 0.62 USD Billion in 2024 to 1.12 USD Billion by 2035. Read More

UK Ophthalmic Drugs Market

ID: MRFR/Pharma/43556-HCR

200 Pages

Vikita Thakur

Last Updated: April 06, 2026

UK Ophthalmic Drugs Market Research Report By Dosage Form (Eye Drops, Eye Ointments, Eye Solutions, Gels, Capsules Tablets, Others), By Product Type (Prescription Drug, OTC Drug), By Drug Class (Antibiotics, Anti-Inflammatory, Anti-Glaucoma, Others), By Indication (Glaucoma, Retinal Disorder, Dry Eye, Eye Allergy, Others) and By Distribution Channels (Hospital pharmacies, Drug stores, Online pharmacies, Others) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Anti-Inflammatory
  2. 4.1.2 Antibiotic
  3. 4.1.3 Antiglaucoma
  4. 4.1.4 Lubricants
  5. 4.1.5 Antiviral
2. 4.2 Healthcare, BY Formulation (USD Billion)
  1. 4.2.1 Eye Drops
  2. 4.2.2 Ointments
  3. 4.2.3 Gels
  4. 4.2.4 Injectables
  5. 4.2.5 Implants
3. 4.3 Healthcare, BY Route of Administration (USD Billion)
  1. 4.3.1 Topical
  2. 4.3.2 Systemic
  3. 4.3.3 Intravitreal
  4. 4.3.4 Subconjunctival
  5. 4.3.5 Periocular
4. 4.4 Healthcare, BY Therapeutic Area (USD Billion)
  1. 4.4.1 Glaucoma
  2. 4.4.2 Infection
  3. 4.4.3 Dry Eye Syndrome
  4. 4.4.4 Allergic Conjunctivitis
  5. 4.4.5 Retinal Disorders
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Allergan (IE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bausch Health (CA)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Santen Pharmaceutical (JP)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Hoya Corporation (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck & Co. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Pfizer (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Johnson & Johnson (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY APPLICATION
3. 6.3 UK MARKET ANALYSIS BY FORMULATION
4. 6.4 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 UK MARKET ANALYSIS BY THERAPEUTIC AREA
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
14. 6.14 HEALTHCARE, BY FORMULATION, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY FORMULATION, 2024 TO 2035 (USD Billion)
16. 6.16 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
18. 6.18 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  2. 7.2.2 BY FORMULATION, 2026-2035 (USD Billion)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
  4. 7.2.4 BY THERAPEUTIC AREA, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

Anti-Inflammatory
Antibiotic
Antiglaucoma
Lubricants
Antiviral

Healthcare By Formulation (USD Billion, 2026-2035)

Eye Drops
Ointments
Gels
Injectables
Implants

Healthcare By Route of Administration (USD Billion, 2026-2035)

Topical
Systemic
Intravitreal
Subconjunctival
Periocular

Healthcare By Therapeutic Area (USD Billion, 2026-2035)

Glaucoma
Infection
Dry Eye Syndrome
Allergic Conjunctivitis
Retinal Disorders

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”